Videos

Neurology News Network for the week ending June 11, 2022. [WATCH TIME: 3 minutes]

Robert Fox, MD, shared the details of the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis, presented at the CMSC 2022 Annual Meeting.

The president and chief executive officer of Mapi Pharma discussed the differences and additional benefits from glatiramer acetate depot, a new intramuscular extended-release version of the known multiple sclerosis medication. [WATCH TIME: 4 minutes]

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]

Kelly Knupp, MD; Joseph E. Sullivan, MD; and Mary Anne Meskis review diagnosis of Dravet syndrome and the role of genetic testing.

Dr Regina Berkovich evaluates the use of mRNA COVID-19 vaccines in patients treated with high efficacy disease-modifying therapies for MS.

Kelly Knupp, MD, provides an overview of Dravet syndrome and shares insight on discerning the diagnosis of disease from febrile seizures.

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]

Barry A. Hendin, MD, reviews guidance on COVID-19 vaccines for patients with MS, including highlights from the AAN position statement.

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the hot topics at the American Headache Society Annual Scientific Meeting, including a presentation on the prevalence of status migrainosus. [WATCH TIME: 4 minutes]

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine shared his insight into his keynote address at the American Headache Society Annual Scientific Meeting. [WATCH TIME: 8 minutes]

Daniel Kantor, MD, discussed the data from his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis, and what questions are still lingering among the clinical community.

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the need for improved tools to evaluate and treat sleep disorders in patients with Alzheimer disease. [WATCH TIME: 3 minutes]

Drs Obeidat and Okai share clinical pearls for physicians taking care of patients with MS.

Two MS experts discuss use and efficacy of vaccinations in patients with MS, especially in patients who are on oral DMTs.

Drs Okai and Obeidat share their excitement about an emerging new drug class for the treatment of MS.

The associate clinical professor at the University of South Carolina School of Medicine discussed how JZP-258’s clinical profile has expanded since its original approval for narcolepsy, and whether it makes sense for all patients to consider. [WATCH TIME: 3 minutes]

Daniel Kantor, MD, discussed his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis who are being treated with sphingosine 1 phosphate receptor modulators.

The associate clinical professor at the University of South Carolina School of Medicine provided context on 2 analyses presented at SLEEP 2022 that highlighted JZP-258’s impact in patients with idiopathic hypersomnia. [WATCH TIME: 2 minutes]

Experts in movement disorders share the importance of multidisciplinary team collaboration for the management of OFF episodes and shared-decision making for treating Parkinson disease.

Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, comment on therapeutic obstacles in treating OFF episodes and how to optimize the management of patients with Parkinson disease.

Rajesh Pahwa, MD, leads a discussion on approaching conversations about ON and OFF episodes in Parkinson disease throughout a patient’s treatment journey.

The graduate student at the University of Michigan provided insight on her study examining longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders. [WATCH TIME: 3 minutes]

Jeffrey Cohen, MD, spoke about the topic of his CMSC Presidential Lecture at the 2022 annual meeting, stem cell transplantation in multiple sclerosis, and what questions remain unanswered in this realm of treatment.

The director of the Sleep Disorders program at the University of Miami discussed his research regarding the association of sleep disordered breathing and total brain volumes in Latino individuals. [WATCH TIME: 3 minutes]

The assistant professor of neurology at the University of Michigan provided context on a previous study which suggested that treatment of obstructive sleep apnea may reduce the risk of subsequent dementia. [WATCH TIME: 3 minutes]

Jeffrey Cohen, MD, shared his perspective on the current use and study of stem cells for the treatment of multiple sclerosis, which he covered in the CMSC Presidential Lecture at the 2022 annual meeting.

The postdoctoral researcher at the Johns Hopkins Multiple Sclerosis Center shared his perspective on the use of spinal cord atrophy in clinical practice to measure disease progression in MS and how it might become more accessible. [WATCH TIME: 4 minutes]

Drs Barry A. Hendin and Regina Berkovich comment on the management and treatment of chronic smoldering inflammation with high efficacy therapies.

Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review clinical implications of real-world data on the use of cladribine and other DMTs in patients with relapsing MS that were presented at ACTRIMS 2022.